IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9771625 B1

PDFFull Text
Date of Patent:
Sep. 26, 2017

Filed:

Jul. 26, 2012

Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer

Applicants:

Jean C. Shih, Beverly Hills, CA (US);

Leland Chung, Los Angeles, CA (US);

Haiyen E. Zhau, Los Angeles, CA (US);

Boyang Jason Wu, Los Angeles, CA (US);

Bogdan Z. Olenyuk, Sierra Madre, CA (US);

Inventors:

Jean C. Shih, Beverly Hills, CA (US);

Leland Chung, Los Angeles, CA (US);

Haiyen E. Zhau, Los Angeles, CA (US);

Boyang Jason Wu, Los Angeles, CA (US);

Bogdan Z. Olenyuk, Sierra Madre, CA (US);

Assignee:

UNIVERSITY OF SOUTHERN CALIFORNIA, Los Angeles, CA (US);

Attorney:

DLA Piper LLP (US)

Primary Examiner:

Nissa Westerberg

Int. Cl.
CPC ...
A61K 31/405 (2006.01); A61K 31/352 (2006.01); A61K 31/357 (2006.01); A61K 31/381 (2006.01); C12N 15/113 (2010.01); A61K 31/366 (2006.01); A61K 31/5375 (2006.01); A61K 31/713 (2006.01); A61K 47/48 (2006.01); A61K 49/00 (2006.01);
U.S. Cl.
CPC ...
C12Y 104/03004 (2013.01); A61K 31/352 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/381 (2013.01); A61K 31/405 (2013.01); A61K 31/5375 (2013.01); A61K 31/713 (2013.01); A61K 47/48061 (2013.01); A61K 49/0032 (2013.01); C12N 15/1137 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01);
Abstract

A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for treating cancer by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation it in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for monitoring treatment progress in a cancer patient by monitoring the changes in MAO activity, methods for screening patients who are at risk of cancer or differentiating different forms of cancer by assaying the level and location of MAO activity.

Find Patent Forward Citations

Loading…